2026 Q1 -tulosraportti
41 päivää sitten
‧29 min
Tarjoustasot
Ei dataa
Viimeisimmät kaupat
| Aika | Hinta | Määrä | Ostaja | Myyjä |
|---|---|---|---|---|
| - | - | - | - |
Huomioi, että vaikka osakkeisiin säästäminen on pitkällä aikavälillä tuottanut hyvin, tulevasta tuotosta ei ole takeita. On olemassa riski, että et saa sijoittamiasi varoja takaisin.
Välittäjätilasto
Dataa ei löytynyt
Yhtiötapahtumat
Datan lähde: FactSet, Quartr| Seuraava tapahtuma | |
|---|---|
2026 Q2 -tulosraportti 20.8. |
| Menneet tapahtumat | ||
|---|---|---|
2026 Q1 -tulosraportti 21.5. | ||
2025 Q4 -tulosraportti 26.3. | ||
2025 Q3 -tulosraportti 19.11.2025 | ||
2025 Q2 -tulosraportti 15.8.2025 | ||
2025 Q1 -tulosraportti 8.5.2025 |
Asiakkaat katsoivat myös
Foorumi
Liity keskusteluun Nordnet Socialissa
Kirjaudu
·15 t sitten1 juli 2026 Newsletter Dear Shareholder, As we move through 2026, we are pleased to share an update on BioPorto's continued development and strategic progress. The first half of the year has been characterized by disciplined execution, important clinical and regulatory progress, and a sharper organizational focus on our core mission; improving kidney health and patient outcomes. Since the beginning of the year, our work has been guided by our "Forward" strategy and our ambition to establish NGAL as a standard-of-care biomarker in relation to acute kidney injury (AKI). The "Forward" strategy was announced in November 2025 and focused on creating market access and commercializing the biomarker that BioPorto has developed. Progress in the U.S. market The U.S. remains a key priority for BioPorto and an important growth opportunity from both a market access and commercial point of view. In the first half of 2026, we reported preliminary results from our adult NGAL cutoff study, which supported the clinical value of NGAL in identifying patients at risk for AKI. Following interactions with the U.S. Food and Drug Administration (FDA), we will initiate the validation study in the adult segment. All with a focus on gaining access to the much larger adult portion of the market. At the same time, we continue to build our commercial understanding through increased adoption of NGAL in the research-use-only (RUO) segment. We are following our plan to have more than 60 U.S. university hospitals by the end of 2026. Clinical and Scientific Developments The broader clinical environment around AKI continues to evolve positively. The recently published draft of the updated KDIGO guidelines highlights a continued shift towards biomarker-driven diagnostic methods and improved clinical decision-making. The final KDIGO guidelines are expected to be published towards the end of the year. We see this development as support for BioPorto's NGAL platform and believe that it can help increase awareness and support the long-term use of biomarker-based diagnostics – such as the company's biomarker – and thereby support long-term value creation for our shareholders. Building a Scalable Organization Preparing the company for growth remains a key priority. During 2026, we completed the relocation of R&D activities from the U.S. to Denmark and strengthened capabilities in project management, design control, and research through targeted hirings. These investments help create a stronger and more scalable organization for the future. We continued to strengthen the company's operational foundation through improved processes, quality systems, and compliance practices. The voluntary recall, announced in June 2026, should be seen in this context. It was a proactive and responsible action that reflected our commitment to high standards of product quality and patient safety and thereby supported long-term value creation for our shareholders. Our "Forward" Strategy and Focused Execution In April, we completed the divestment of our antibody business. This refined our strategic focus and strengthened our financial flexibility. By divesting a non-core activity, we focused our capital and organizational resources on the "Forward" strategy. We remain committed to disciplined execution in relation to our strategic long-term ambitions: - Revenue growth as NGAL adoption increases; deliver revenue in 2028 of DKK 135-185 million - Leverage the advantage of scalability; deliver an EBITDA margin of at least 15 % in 2028 - Create sustainability; deliver positive cash flow break-even in the second half of 2028 We welcome and greatly appreciate the continued trust and support from our shareholders and value the ongoing dialogue we have with you. We look forward to updating you further as we move through what we expect will be an important and milestone-rich period for BioPorto. I wish you all a wonderful summer. Carsten Buhl, CEO
·26.6.It works. I just wanted to make sure before I announced it. I have previously written that there are a couple of platforms where we can see if there are bids for the NGAL test and how it will go with getting new hospitals to participate in RUO NGAL testing. Like everything else in medicine, it's complicated, but that shouldn't stop you from keeping an eye on it yourself. Regarding TED, it's a hospital or similar that ensures to get bids from companies that want to sell NGAL tests for the project, which can be a larger or smaller project. Regarding clinicaltrials.gov, we can see when Bioporto has received all test participants for NGAL for adults. TED https://ted.europa.eu/da/ USA https://clinicaltrials.gov/- ·18.6.It was very positive that there was a full house. A full house with over 100 participants for the expert session "Beyond creatinine: redefining hashtag#AKI diagnosis and decision-making in the hashtag#PICU" https://www.linkedin.com/company/bioporto-diagnostics-a-s/posts/?feedView=all
- ·17.6.The internet is God's gift to us investors. I may have found a website that informs every time Bioporto closes a contract, with the NGAL test, and when researchers want to use the NGAL test for their research, in any country within the EU. If it turns out that it works, would you then want this information? Please write below.It will probably take a few months before there are hits, if it turns out that we can benefit from this platform.
- ·16.6.I would like to make a correction to how it works when Bioporto sells NGAL tests for adults, only for research use. I have previously stated that Bioporto will sell NGAL tests for adults, only for research, to American hospitals, even though the FDA has not yet approved the test, and that is also correct, but I had understood that it was a gray area that the hospitals were moving into, and that is incorrect. The correct information is. If a hospital in the USA has a laboratory that is advanced enough and approved by the FDA for research, such as NGAL tests for adults, then it is completely legal. They call it CLIA. In the USA there are 490 university hospitals, all of which are allowed to use the NGAL test, only for research. Some of these university hospitals own a number of smaller hospitals and other treatment centers, and they can also use the NGAL test for adults, because the university hospitals run the test for them. The purely public hospitals must politely wait until the NGAL test for adults is approved by the FDA. That is the reason why Bioporto maintains its expectations and holds on to 60+ hospitals. CLIA https://www.cms.gov/regulations-and-guidance/legislation/clia/downloads/ldt-and-clia_faqs.pdf Number of university hospitals https://www.aamc.org/about-us/institutional-membership Example of a university hospital that owns smaller treatment centers https://www.massgeneralbrigham.org/en/patient-care/services-and-specialties/find-a-location/our-hospitalsNow that we have a handle on how it works over there, we should also keep an eye on the progress of getting more hospitals to participate in the research.
Yllä olevat kommentit ovat peräisin Nordnetin sosiaalisen verkoston Nordnet Socialin käyttäjiltä, eikä niitä ole muokattu eikä Nordnet ole tarkastanut niitä etukäteen. Ne eivät tarkoita, että Nordnet tarjoaisi sijoitusneuvoja tai sijoitussuosituksia. Nordnet ei ota vastuuta kommenteista.
Uutiset
Tämän sivun uutiset ja/tai sijoitussuositukset tai otteet niistä sekä niihin liittyvät linkit ovat mainitun tahon tuottamia ja toimittamia. Nordnet ei ole osallistunut materiaalin laatimiseen, eikä ole tarkistanut sen sisältöä tai tehnyt sisältöön muutoksia. Lue lisää sijoitussuosituksista.
2026 Q1 -tulosraportti
41 päivää sitten
‧29 min
Uutiset
Tämän sivun uutiset ja/tai sijoitussuositukset tai otteet niistä sekä niihin liittyvät linkit ovat mainitun tahon tuottamia ja toimittamia. Nordnet ei ole osallistunut materiaalin laatimiseen, eikä ole tarkistanut sen sisältöä tai tehnyt sisältöön muutoksia. Lue lisää sijoitussuosituksista.
Foorumi
Liity keskusteluun Nordnet Socialissa
Kirjaudu
- ·15 t sitten1 juli 2026 Newsletter Dear Shareholder, As we move through 2026, we are pleased to share an update on BioPorto's continued development and strategic progress. The first half of the year has been characterized by disciplined execution, important clinical and regulatory progress, and a sharper organizational focus on our core mission; improving kidney health and patient outcomes. Since the beginning of the year, our work has been guided by our "Forward" strategy and our ambition to establish NGAL as a standard-of-care biomarker in relation to acute kidney injury (AKI). The "Forward" strategy was announced in November 2025 and focused on creating market access and commercializing the biomarker that BioPorto has developed. Progress in the U.S. market The U.S. remains a key priority for BioPorto and an important growth opportunity from both a market access and commercial point of view. In the first half of 2026, we reported preliminary results from our adult NGAL cutoff study, which supported the clinical value of NGAL in identifying patients at risk for AKI. Following interactions with the U.S. Food and Drug Administration (FDA), we will initiate the validation study in the adult segment. All with a focus on gaining access to the much larger adult portion of the market. At the same time, we continue to build our commercial understanding through increased adoption of NGAL in the research-use-only (RUO) segment. We are following our plan to have more than 60 U.S. university hospitals by the end of 2026. Clinical and Scientific Developments The broader clinical environment around AKI continues to evolve positively. The recently published draft of the updated KDIGO guidelines highlights a continued shift towards biomarker-driven diagnostic methods and improved clinical decision-making. The final KDIGO guidelines are expected to be published towards the end of the year. We see this development as support for BioPorto's NGAL platform and believe that it can help increase awareness and support the long-term use of biomarker-based diagnostics – such as the company's biomarker – and thereby support long-term value creation for our shareholders. Building a Scalable Organization Preparing the company for growth remains a key priority. During 2026, we completed the relocation of R&D activities from the U.S. to Denmark and strengthened capabilities in project management, design control, and research through targeted hirings. These investments help create a stronger and more scalable organization for the future. We continued to strengthen the company's operational foundation through improved processes, quality systems, and compliance practices. The voluntary recall, announced in June 2026, should be seen in this context. It was a proactive and responsible action that reflected our commitment to high standards of product quality and patient safety and thereby supported long-term value creation for our shareholders. Our "Forward" Strategy and Focused Execution In April, we completed the divestment of our antibody business. This refined our strategic focus and strengthened our financial flexibility. By divesting a non-core activity, we focused our capital and organizational resources on the "Forward" strategy. We remain committed to disciplined execution in relation to our strategic long-term ambitions: - Revenue growth as NGAL adoption increases; deliver revenue in 2028 of DKK 135-185 million - Leverage the advantage of scalability; deliver an EBITDA margin of at least 15 % in 2028 - Create sustainability; deliver positive cash flow break-even in the second half of 2028 We welcome and greatly appreciate the continued trust and support from our shareholders and value the ongoing dialogue we have with you. We look forward to updating you further as we move through what we expect will be an important and milestone-rich period for BioPorto. I wish you all a wonderful summer. Carsten Buhl, CEO
- ·26.6.It works. I just wanted to make sure before I announced it. I have previously written that there are a couple of platforms where we can see if there are bids for the NGAL test and how it will go with getting new hospitals to participate in RUO NGAL testing. Like everything else in medicine, it's complicated, but that shouldn't stop you from keeping an eye on it yourself. Regarding TED, it's a hospital or similar that ensures to get bids from companies that want to sell NGAL tests for the project, which can be a larger or smaller project. Regarding clinicaltrials.gov, we can see when Bioporto has received all test participants for NGAL for adults. TED https://ted.europa.eu/da/ USA https://clinicaltrials.gov/
- ·18.6.It was very positive that there was a full house. A full house with over 100 participants for the expert session "Beyond creatinine: redefining hashtag#AKI diagnosis and decision-making in the hashtag#PICU" https://www.linkedin.com/company/bioporto-diagnostics-a-s/posts/?feedView=all
- ·17.6.The internet is God's gift to us investors. I may have found a website that informs every time Bioporto closes a contract, with the NGAL test, and when researchers want to use the NGAL test for their research, in any country within the EU. If it turns out that it works, would you then want this information? Please write below.It will probably take a few months before there are hits, if it turns out that we can benefit from this platform.
- ·16.6.I would like to make a correction to how it works when Bioporto sells NGAL tests for adults, only for research use. I have previously stated that Bioporto will sell NGAL tests for adults, only for research, to American hospitals, even though the FDA has not yet approved the test, and that is also correct, but I had understood that it was a gray area that the hospitals were moving into, and that is incorrect. The correct information is. If a hospital in the USA has a laboratory that is advanced enough and approved by the FDA for research, such as NGAL tests for adults, then it is completely legal. They call it CLIA. In the USA there are 490 university hospitals, all of which are allowed to use the NGAL test, only for research. Some of these university hospitals own a number of smaller hospitals and other treatment centers, and they can also use the NGAL test for adults, because the university hospitals run the test for them. The purely public hospitals must politely wait until the NGAL test for adults is approved by the FDA. That is the reason why Bioporto maintains its expectations and holds on to 60+ hospitals. CLIA https://www.cms.gov/regulations-and-guidance/legislation/clia/downloads/ldt-and-clia_faqs.pdf Number of university hospitals https://www.aamc.org/about-us/institutional-membership Example of a university hospital that owns smaller treatment centers https://www.massgeneralbrigham.org/en/patient-care/services-and-specialties/find-a-location/our-hospitalsNow that we have a handle on how it works over there, we should also keep an eye on the progress of getting more hospitals to participate in the research.
Yllä olevat kommentit ovat peräisin Nordnetin sosiaalisen verkoston Nordnet Socialin käyttäjiltä, eikä niitä ole muokattu eikä Nordnet ole tarkastanut niitä etukäteen. Ne eivät tarkoita, että Nordnet tarjoaisi sijoitusneuvoja tai sijoitussuosituksia. Nordnet ei ota vastuuta kommenteista.
Tarjoustasot
Ei dataa
Viimeisimmät kaupat
| Aika | Hinta | Määrä | Ostaja | Myyjä |
|---|---|---|---|---|
| - | - | - | - |
Huomioi, että vaikka osakkeisiin säästäminen on pitkällä aikavälillä tuottanut hyvin, tulevasta tuotosta ei ole takeita. On olemassa riski, että et saa sijoittamiasi varoja takaisin.
Välittäjätilasto
Dataa ei löytynyt
Asiakkaat katsoivat myös
Yhtiötapahtumat
Datan lähde: FactSet, Quartr| Seuraava tapahtuma | |
|---|---|
2026 Q2 -tulosraportti 20.8. |
| Menneet tapahtumat | ||
|---|---|---|
2026 Q1 -tulosraportti 21.5. | ||
2025 Q4 -tulosraportti 26.3. | ||
2025 Q3 -tulosraportti 19.11.2025 | ||
2025 Q2 -tulosraportti 15.8.2025 | ||
2025 Q1 -tulosraportti 8.5.2025 |
2026 Q1 -tulosraportti
41 päivää sitten
‧29 min
Uutiset
Tämän sivun uutiset ja/tai sijoitussuositukset tai otteet niistä sekä niihin liittyvät linkit ovat mainitun tahon tuottamia ja toimittamia. Nordnet ei ole osallistunut materiaalin laatimiseen, eikä ole tarkistanut sen sisältöä tai tehnyt sisältöön muutoksia. Lue lisää sijoitussuosituksista.
Yhtiötapahtumat
Datan lähde: FactSet, Quartr| Seuraava tapahtuma | |
|---|---|
2026 Q2 -tulosraportti 20.8. |
| Menneet tapahtumat | ||
|---|---|---|
2026 Q1 -tulosraportti 21.5. | ||
2025 Q4 -tulosraportti 26.3. | ||
2025 Q3 -tulosraportti 19.11.2025 | ||
2025 Q2 -tulosraportti 15.8.2025 | ||
2025 Q1 -tulosraportti 8.5.2025 |
Foorumi
Liity keskusteluun Nordnet Socialissa
Kirjaudu
- ·15 t sitten1 juli 2026 Newsletter Dear Shareholder, As we move through 2026, we are pleased to share an update on BioPorto's continued development and strategic progress. The first half of the year has been characterized by disciplined execution, important clinical and regulatory progress, and a sharper organizational focus on our core mission; improving kidney health and patient outcomes. Since the beginning of the year, our work has been guided by our "Forward" strategy and our ambition to establish NGAL as a standard-of-care biomarker in relation to acute kidney injury (AKI). The "Forward" strategy was announced in November 2025 and focused on creating market access and commercializing the biomarker that BioPorto has developed. Progress in the U.S. market The U.S. remains a key priority for BioPorto and an important growth opportunity from both a market access and commercial point of view. In the first half of 2026, we reported preliminary results from our adult NGAL cutoff study, which supported the clinical value of NGAL in identifying patients at risk for AKI. Following interactions with the U.S. Food and Drug Administration (FDA), we will initiate the validation study in the adult segment. All with a focus on gaining access to the much larger adult portion of the market. At the same time, we continue to build our commercial understanding through increased adoption of NGAL in the research-use-only (RUO) segment. We are following our plan to have more than 60 U.S. university hospitals by the end of 2026. Clinical and Scientific Developments The broader clinical environment around AKI continues to evolve positively. The recently published draft of the updated KDIGO guidelines highlights a continued shift towards biomarker-driven diagnostic methods and improved clinical decision-making. The final KDIGO guidelines are expected to be published towards the end of the year. We see this development as support for BioPorto's NGAL platform and believe that it can help increase awareness and support the long-term use of biomarker-based diagnostics – such as the company's biomarker – and thereby support long-term value creation for our shareholders. Building a Scalable Organization Preparing the company for growth remains a key priority. During 2026, we completed the relocation of R&D activities from the U.S. to Denmark and strengthened capabilities in project management, design control, and research through targeted hirings. These investments help create a stronger and more scalable organization for the future. We continued to strengthen the company's operational foundation through improved processes, quality systems, and compliance practices. The voluntary recall, announced in June 2026, should be seen in this context. It was a proactive and responsible action that reflected our commitment to high standards of product quality and patient safety and thereby supported long-term value creation for our shareholders. Our "Forward" Strategy and Focused Execution In April, we completed the divestment of our antibody business. This refined our strategic focus and strengthened our financial flexibility. By divesting a non-core activity, we focused our capital and organizational resources on the "Forward" strategy. We remain committed to disciplined execution in relation to our strategic long-term ambitions: - Revenue growth as NGAL adoption increases; deliver revenue in 2028 of DKK 135-185 million - Leverage the advantage of scalability; deliver an EBITDA margin of at least 15 % in 2028 - Create sustainability; deliver positive cash flow break-even in the second half of 2028 We welcome and greatly appreciate the continued trust and support from our shareholders and value the ongoing dialogue we have with you. We look forward to updating you further as we move through what we expect will be an important and milestone-rich period for BioPorto. I wish you all a wonderful summer. Carsten Buhl, CEO
- ·26.6.It works. I just wanted to make sure before I announced it. I have previously written that there are a couple of platforms where we can see if there are bids for the NGAL test and how it will go with getting new hospitals to participate in RUO NGAL testing. Like everything else in medicine, it's complicated, but that shouldn't stop you from keeping an eye on it yourself. Regarding TED, it's a hospital or similar that ensures to get bids from companies that want to sell NGAL tests for the project, which can be a larger or smaller project. Regarding clinicaltrials.gov, we can see when Bioporto has received all test participants for NGAL for adults. TED https://ted.europa.eu/da/ USA https://clinicaltrials.gov/
- ·18.6.It was very positive that there was a full house. A full house with over 100 participants for the expert session "Beyond creatinine: redefining hashtag#AKI diagnosis and decision-making in the hashtag#PICU" https://www.linkedin.com/company/bioporto-diagnostics-a-s/posts/?feedView=all
- ·17.6.The internet is God's gift to us investors. I may have found a website that informs every time Bioporto closes a contract, with the NGAL test, and when researchers want to use the NGAL test for their research, in any country within the EU. If it turns out that it works, would you then want this information? Please write below.It will probably take a few months before there are hits, if it turns out that we can benefit from this platform.
- ·16.6.I would like to make a correction to how it works when Bioporto sells NGAL tests for adults, only for research use. I have previously stated that Bioporto will sell NGAL tests for adults, only for research, to American hospitals, even though the FDA has not yet approved the test, and that is also correct, but I had understood that it was a gray area that the hospitals were moving into, and that is incorrect. The correct information is. If a hospital in the USA has a laboratory that is advanced enough and approved by the FDA for research, such as NGAL tests for adults, then it is completely legal. They call it CLIA. In the USA there are 490 university hospitals, all of which are allowed to use the NGAL test, only for research. Some of these university hospitals own a number of smaller hospitals and other treatment centers, and they can also use the NGAL test for adults, because the university hospitals run the test for them. The purely public hospitals must politely wait until the NGAL test for adults is approved by the FDA. That is the reason why Bioporto maintains its expectations and holds on to 60+ hospitals. CLIA https://www.cms.gov/regulations-and-guidance/legislation/clia/downloads/ldt-and-clia_faqs.pdf Number of university hospitals https://www.aamc.org/about-us/institutional-membership Example of a university hospital that owns smaller treatment centers https://www.massgeneralbrigham.org/en/patient-care/services-and-specialties/find-a-location/our-hospitalsNow that we have a handle on how it works over there, we should also keep an eye on the progress of getting more hospitals to participate in the research.
Yllä olevat kommentit ovat peräisin Nordnetin sosiaalisen verkoston Nordnet Socialin käyttäjiltä, eikä niitä ole muokattu eikä Nordnet ole tarkastanut niitä etukäteen. Ne eivät tarkoita, että Nordnet tarjoaisi sijoitusneuvoja tai sijoitussuosituksia. Nordnet ei ota vastuuta kommenteista.
Tarjoustasot
Ei dataa
Viimeisimmät kaupat
| Aika | Hinta | Määrä | Ostaja | Myyjä |
|---|---|---|---|---|
| - | - | - | - |
Huomioi, että vaikka osakkeisiin säästäminen on pitkällä aikavälillä tuottanut hyvin, tulevasta tuotosta ei ole takeita. On olemassa riski, että et saa sijoittamiasi varoja takaisin.
Välittäjätilasto
Dataa ei löytynyt